Combined Application of Cold Physical Plasma and Chemotherapeutics against Chondrosarcoma Cells

Author:

Nitsch Andreas1ORCID,Qarqash Sara1ORCID,Schulze Frank1ORCID,Nonnenmacher Lars1,Bekeschus Sander23ORCID,Tzvetkov Mladen V.4,Wassilew Georgi I.1,Haralambiev Lyubomir1ORCID

Affiliation:

1. Center for Orthopedics, Trauma Surgery and Rehabilitation Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Str., 17475 Greifswald, Germany

2. ZIK Plasmatis, Leibniz Institute for Plasma Science and Technology (INP), Felix-Hausdorff-Straße 2, 17489 Greifswald, Germany

3. Clinic and Policlinic for Dermatology and Venerology, Rostock University Medical Center, Strempelstr. 13, 18057 Rostock, Germany

4. Department of General Pharmacology, Institute of Pharmacology, Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald, 17487 Greifswald, Germany

Abstract

Chondrosarcoma (CS) is a rare malignant bone sarcoma that primarily affects cartilage cells in the femur and pelvis. While most subtypes exhibit slow growth with a very good prognosis, some aggressive subtypes have a poorer overall survival. CS is known for its resistance to chemotherapy and radiotherapy, leaving surgery as the sole effective therapeutic option. Cold physical plasma (CPP) has been explored in vitro as a potential therapy, demonstrating positive anti-tumor effects on CS cells. This study investigated the synergistic effects of combining CPP with cytostatics on CS cells. The chemotherapeutic agents cisplatin, doxorubicin, and vincristine were applied to two CS cell lines (CAL-78 and SW1353). After determining their IC20 and IC50, they were combined with CPP in both cell lines to assess their impact on the cell proliferation, viability, metabolism, and apoptosis. This combined approach significantly reduced the cell proliferation and viability while increasing the apoptosis signals compared to cytostatic therapy alone. The combination of CPP and chemotherapeutic drugs shows promise in targeting chemoresistant CS cells, potentially improving the prognosis for patients in clinical settings.

Funder

German Research Foundation

University Medicine Greifswald

Publisher

MDPI AG

Reference73 articles.

1. Limaiem, F., Davis, D.D., and Sticco, K.L. (2024). Chondrosarcoma. StatPearls, StatPearls Publishing.

2. The National Incidence of Chondrosarcoma of Bone; a Review;Thorkildsen;Acta Oncol.,2023

3. Cosci, I., Del Fiore, P., Mocellin, S., and Ferlin, A. (2024). Gender Differences in Soft Tissue and Bone Sarcoma: A Narrative Review. Cancers, 16.

4. Chondrosarcoma;Weinschenk;JAAOS—J. Am. Acad. Orthop. Surg.,2021

5. Osteosarcoma, Chondrosarcoma, and Ewing’s Sarcoma: National Cancer Data Base Report;Damron;Clin. Orthop. Relat. Res.®,2007

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3